Urogen Story

<div class='circular--portrait' style='background:#169D0B;color: #FFFFF0;font-size:4em;'>UP</div>
URGN -- USA Stock  

USD 18.16  0.53  3.01%

A current spike in volatility has left many institutional investors looking confused. In this story, we will outline Urogen Pharma. What exactly are Urogen Pharma shareholders getting in April? Urogen Pharma is at this time traded for 18.05. The entity stock is not elastic to its hype. The average elasticity to hype of competition is -0.04. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is at this time at -0.01%. The volatility of relative hype elasticity to Urogen Pharma is about 93.3%. The volatility of related hype on Urogen Pharma is about 93.3% with expected price after next announcement by competition of 18.01 Given the investment horizon of 30 days the next forecasted press release will be in about 5 days.
Published over three weeks ago
View all stories for Urogen Pharma | View All Stories
Do you have a personal attachment to Urogen Pharma?
This firm's average rating is Buy from 4 analysts.
Our advice tool can cross-verify current analyst consensus on Urogen Pharma and to analyze the firm potential to grow in the current economic cycle.
The successful prediction of Urogen Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Urogen Pharma, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Urogen Pharma based on Urogen Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Urogen Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Urogen Pharma's related companies.

Use Technical Analysis to project Urogen expected Price

Urogen Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Urogen Pharma technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Urogen Pharma trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Urogen utilizes its cash?

To perform a cash flow analysis of Urogen Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Urogen Pharma is receiving and how much cash it distributes out in a given period. The Urogen Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Smith Jason Drew of 2500 shares of Urogen Pharma subject to Rule 16b-3

Legal trades by Urogen Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Urogen insider trading alert for grant of restricted stock units by Smith Jason Drew, General Counsel, on 2nd of February 2021. This event was filed by Urogen Pharma Ltd with SEC on 2021-02-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Urogen Pharma Investor Appetite?

The company reported the previous year's revenue of 3.83 M. Net Loss for the year was (136.93 M) with profit before overhead, payroll, taxes, and interest of 18 K.

A growth case for Urogen Pharma

Latest treynor ratio indicator falls down to -0.41. Possible price upswing? Urogen Pharma shows above-average downside volatility for the selected time horizon. We advise investors to inspect Urogen Pharma further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Urogen Pharma future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Urogen Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Urogen Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Urogen Pharma

When is the right time to buy or sell Urogen Pharma? Buying stocks such as Urogen Pharma isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis.
The inconsistency in the assessment between current Urogen valuation and our trade advice on Urogen Pharma is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Urogen Pharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Urogen Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com